Bernstein Liebhard LLP Files GranuFlo Lawsuit Alleging Dialysis Death of Georgia Man
The nationwide law firm of Bernstein Liebhard LLP has joined a thriving GranuFlo lawsuit litigation that now includes more than 650 federally-filed claims over the dialysis drug, the Firm reports.
According to court records from March 24, 2014, the Firm filed a GranuFlo lawsuit in the U.S. District Court, District of Massachusetts on behalf of a man in Georgia who allegedly suffered an episode of cardiac arrest in January 2012 that eventually turned fatal. His injuries occurred within 72 hours of receiving GranuFlo or NaturaLyte during dialysis, according to the case, and two months prior to a warning from Fresenius Medical Care that serious heart problems may be associated with use of the acid concentrates.
According to the manufacturer’s Urgent Product Notification on March 29, 2012, side effects of GranuFlo and NaturaLyte may stem from the drugs’ high amount of an ingredient the body converts to bicarbonate. Although similar dialysis medications contain this ingredient, Fresenius noted in its public alert that its products contain more, which may put patients at a heightened risk for metabolic alkalosis, a condition linked to heart attacks, strokes, and other serious cardiovascular problems that may result in sudden cardiac death, in the worst-case scenario.
The U.S. Food and Drug Administration (FDA) granted this notification Class I recall status on June 25, 2012 after determining that heart problems associated with GranuFlo and NaturaLyte may be serious, and potentially fatal. It is noteworthy to add that a Class I recall from the FDA is its most serious category.
GranuFlo Recall Was Issued Too Late, Plaintiffs Allege
Plaintiffs in GranuFlo recall lawsuits, like the one recently filed by Bernstein Liebhard LLP, similarly allege that the March 2012 notification from Fresenius was issued too late, and that thousands of dialysis patients may have been injured, or even died after use of the acid concentrates by then. In addition to thousands of treatment centers owned by the company, which is based in Massachusetts and is considered a leader of dialysis products and services in the U.S., reports indicate that GranuFlo and NaturaLyte were administered in approximately 125,000 customer clinics throughout the country. Around the time of the FDA’s dialysis recall, the federal agency discovered the contents of an internal memo sent in November 2011 that acknowledged 941 patient deaths that occurred in Fresenius clinics.
Filing a GranuFlo Lawsuit
Bernstein Liebhard LLP are actively filing GranuFlo lawsuits alleging strokes, heart attacks and other serious heart problems leading to cardiac death. Call our Firm today at (877) 779-1414 to start the process of filing a case of your own.